Today: 13 June 2026
Browse Category

NASDAQ:ABVX 20 November 2025 - 2 June 2026

Abivax Stock Sees Big After-Hours Moves After Trial Result

Abivax Stock Sees Big After-Hours Moves After Trial Result

Abivax shares plunged 33.7% to $86.01 after hours on Nasdaq despite its ulcerative colitis drug obefazimod hitting the main goal in a 44-week Phase 3 trial. Both 25 mg and 50 mg doses showed over 50% clinical remission versus 10.4% for placebo. No new safety signals reported. Abivax plans a U.S. FDA filing late Q4 2026. Cash reserves stood at €491.6 million at March-end, funding into Q4 2027.
2 June 2026
···
Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax’s U.S.-listed shares fell 3.8% to $133.04 late Wednesday morning, reversing part of a recent surge driven by takeover speculation and index inclusion. Trading volume reached about 348,000 shares as the stock swung between $132.13 and $140.25. Investors await updates on strategic interest and new data for obefazimod, the company’s lead drug candidate.
31 December 2025
··
Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

Abivax (NASDAQ: ABVX) rose about 5.3% to $145.31 in premarket trading Friday, with U.S. markets the main venue as Euronext remained closed for St. Stephen’s Day. The stock has surged in December amid Eli Lilly takeover rumors, recent inclusion in the Nasdaq Biotechnology Index, and ongoing interest in its ulcerative colitis drug obefazimod.
26 December 2025
···
ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

Abivax shares jumped about 10% to $126 in early U.S. premarket trading after reports of renewed takeover speculation involving Eli Lilly and confirmation of Abivax’s addition to the Nasdaq Biotechnology Index. French media said Lilly representatives met with France’s Treasury about a possible acquisition, though Reuters could not confirm the meeting. Both companies declined to comment on the rumors.
22 December 2025
····
ABIVAX Société Anonyme (ABVX) Stock News on Dec. 16, 2025: Shares Slide After Q3 Loss Widens, While Analysts Keep Buy Calls and M&A Talk Lingers

ABIVAX Société Anonyme (ABVX) Stock News on Dec. 16, 2025: Shares Slide After Q3 Loss Widens, While Analysts Keep Buy Calls and M&A Talk Lingers

Abivax shares fell about 5% in U.S. and Paris trading after reporting a nine-month net loss of €254.1 million, up from €136.9 million a year earlier. Cash and cash equivalents stood at €589.7 million as of September 30, expected to fund operations into Q4 2027. Investors weighed widening losses against a strong cash position and ongoing takeover speculation.
16 December 2025
···
Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax shares surged as much as 20% on December 10, 2025, in Paris trading amid market rumors of a possible takeover bid by Eli Lilly. The stock hit a 52-week high near €126.60, with market value reaching about €9.7 billion. Abivax declined to comment, and no formal offer has been announced. U.S.-listed ADRs also jumped over 11% in pre-market trading.
10 December 2025
····
Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025

Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025

Abivax shares surged 8% to $121.94 Thursday afternoon on heavy volume after fresh takeover rumors involving AstraZeneca. The French biotech’s stock is up about 1,450% year-to-date, fueled by strong Phase 3 ulcerative colitis data and M&A speculation. No deal has been confirmed by either company. Intraday volume reached 3.75 million ADSs, far above recent averages.
20 November 2025
··

Stock Market Today

  • SpaceX IPO Faces Centuries-Old Market Challenge: Patient Investors Prevail
    June 13, 2026, 7:22 AM EDT. SpaceX's potential IPO echoes the centuries-old challenge first seen with the Dutch East India Company (VOC) in 1602. Despite VOC's real assets and government backing, its stock took decades to double. Modern IPO data supports similar caution: 60% of IPOs between 1975-2021 ended flat or lower after three years, according to University of Florida research. Market experts caution that most IPOs dip before gains and that well-known large IPOs like US Steel (1901), Ford (1956), and Coinbase (2021) often debut near market peaks, followed by prolonged downturns. Investors eyeing SpaceX should prepare for a long-term, patient approach rather than immediate profits.

Latest articles

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 13.06.2026

13 June 2026
LIVEMarkets rolling coverageStarted: June 13, 2026, 4:00 AM EDTUpdated: June 13, 2026, 7:22 AM EDT SpaceX IPO Faces Centuries-Old Market Challenge: Patient Investors Prevail June 13, 2026, 7:22 AM EDT. SpaceX’s potential IPO echoes the centuries-old challenge first seen with the Dutch East India Company (VOC) in 1602. Despite VOC’s real assets and government backing, its stock took decades to double. Modern IPO data supports similar caution: 60% of IPOs between 1975-2021 ended flat or lower after three years, according to University of Florida research. Market experts caution that most IPOs dip before gains and that well-known large IPOs like
SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

13 June 2026
SGH closed at A$41.51, up 0.70% but underperformed the S&P/ASX 200’s 1.98% surge, as investors weighed solid cash flow and Boral margin gains against a high 36.03 P/E, mixed demand, and M&A risk; the next key catalyst is FY26 results on August 11, with analysts’ average target at A$47.64, 14.76% above Friday’s close.
Go toTop